<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863511</url>
  </required_header>
  <id_info>
    <org_study_id>TUF-01</org_study_id>
    <nct_id>NCT01863511</nct_id>
  </id_info>
  <brief_title>Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure</brief_title>
  <acronym>TUF</acronym>
  <official_title>Primary Mode of Therapy in Acute Decompensated Heart Failure:Comparison Between Usual Care Plus Tolvaptan and Ultrafiltration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christ Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Christ Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients hospitalized with acute decompensated heart failure,volume removal remains the&#xD;
      primary therapeutic objective. The current standard of care remains loop diuretics.The high&#xD;
      likelihood of readmissions and poor outcomes highlights the need to examine and improve&#xD;
      in-hospital protocols for these patients. Ultrafiltration allows for greater volume removal,&#xD;
      less neurohormonal stimulation and greater sodium removal.However it is associated with&#xD;
      increased costs, line complications, and relative immobility during treatment. Tolvaptan in&#xD;
      addition to diuretic therapy has been shown to improve the amount of volume removed compared&#xD;
      to diuretic alone.&#xD;
&#xD;
      The study proposes to compare the strategy of adding tolvaptan to usual care with&#xD;
      ultrafiltration as primary mode of therapy in acute decompensated HF(ADHF) patients.&#xD;
&#xD;
      Hypothesis: addition of tolvaptan to usual care for hospitalized HF patients will result in:&#xD;
&#xD;
        -  greater volume and weight reduction compared with usual care&#xD;
&#xD;
        -  similar efficacy outcomes compared with ultrafiltration, with less complications of&#xD;
           therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design is a prospective randomized open labeled and unblinded comparison of two&#xD;
      different approaches to volume removal. Enrolled patients will be evaluated for target weight&#xD;
      to be removed. Patients will be randomized to usual care (UC), usual care plus tolvaptan&#xD;
      (UC+T) or ultrafiltration (UF), within 12 hours of presentation.&#xD;
&#xD;
      Treatment in the UC and UC+T arms will begin with a furosemide bolus(double the home dose or&#xD;
      if unavailable, 60mg) and continue with a drip(10 or 20 mg/hr). In addition the UC+T group&#xD;
      will be treated with tolvaptan 30 mg orally once daily.&#xD;
&#xD;
      Patients in the UF arm will be treated with UF administered through a brachial line or a&#xD;
      catheter in the internal jugular vein. Loop and thiazide diuretics will be discontinued,&#xD;
      although aldosterole antagonists will be continued.&#xD;
&#xD;
      Urinary neutrophil gelatinase associated lipocalcin(uNGAL)levels are elevated in renal&#xD;
      dysfunction and may be a sensitive biomarker to distinguish between intrinsic renal damage&#xD;
      and reversible, transient prerenal azotemia.Characterizing the changes in uNGAL levels during&#xD;
      the course of ADHF therapy, in comparison with patient weight, BUN and creatinine levels is&#xD;
      an important step in establishing the role of this potential promising biomarker in ADHF&#xD;
      treatment strategies.&#xD;
&#xD;
      Protocol highlights for all patients include:&#xD;
&#xD;
      Baseline labs and daily through day 4 and at discharge(BMP, BNP, CBC, urine creatinine and&#xD;
      sodium, uNGAL)&#xD;
&#xD;
        -  Daily am weights&#xD;
&#xD;
        -  Daily volume status:total intake, urine output, ultrafiltrate volume&#xD;
&#xD;
        -  Collect all urine and ultrafiltrate in a 24 hour collection bag, record volume,&#xD;
           creatinine and Na levels&#xD;
&#xD;
        -  length of stay&#xD;
&#xD;
        -  hospital day 4: Minnesota Living with Heart Failure questionnaire&#xD;
&#xD;
        -  Cost of hospitalization&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net change in weight</measure>
    <time_frame>day 1,2,3,4,5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>net volume loss</measure>
    <time_frame>day 1,2,3,4,5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary NGAL</measure>
    <time_frame>Day 1,2,3,4,5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyspnea score</measure>
    <time_frame>baseline and day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP change from admission to discharge</measure>
    <time_frame>baseline and day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine change</measure>
    <time_frame>Day 1,2,3,4,5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum sodium and potassium changes</measure>
    <time_frame>baseline through day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>day 4 of hospital stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause readmission</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause death</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>nursing intensity</measure>
    <time_frame>day 1,2,3,4,5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>peripheral vs. central access, number of filters used, complications of heparin use</measure>
    <time_frame>day 1,2,3,4,5</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV loop diuretics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care plus tolvaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV loop diuretic plus Tolvaptan 30 mg orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ultrafiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volume removal through a brachial line extended length catheter or a quad lumen catheter via the internal jugular vein</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>loop diuretic</intervention_name>
    <arm_group_label>Usual care plus tolvaptan</arm_group_label>
    <arm_group_label>usual care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tolvaptan</intervention_name>
    <arm_group_label>Usual care plus tolvaptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrafiltration</intervention_name>
    <arm_group_label>ultrafiltration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  2 of 3 physical exam findings of volume overload (rales, JVP over 5 cm and edema)&#xD;
&#xD;
          -  BNP over 300&#xD;
&#xD;
          -  no contraindication to ultrafiltration (line insertion, heparin use)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  serum creatinine &gt; 3mg/dL or Na &gt; 145&#xD;
&#xD;
          -  inotrope or vasopressor dependency&#xD;
&#xD;
          -  active infection, including urinary tract&#xD;
&#xD;
          -  resynchronization therapy or coronary intervention in past 30 days&#xD;
&#xD;
          -  life expectancy less than 6 months&#xD;
&#xD;
          -  hypertrophic obstructive cardiomyopathy with peak resting gradient &gt; 20 mmHg&#xD;
&#xD;
          -  IV contrast or NSAID use in the past 1 week (uNGAL related requirement)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene S Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christ Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Christ Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Eugene Chung</investigator_full_name>
    <investigator_title>Eugene S. Chung MD, FACC</investigator_title>
  </responsible_party>
  <keyword>Treatment options for acute decompensated heart failure</keyword>
  <keyword>Ultrafiltration</keyword>
  <keyword>tolvaptan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

